Home Featured Page 294

Featured

Latest

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

July 2025 Psychedelic Patent Update

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and...

Psychedelics Show Promise for Treating Dementia

Catching Up with the Psychedelic Entourage Effect: Part 3 – Field...

Insight into Ayahuasca’s Antidepressant Effects

New Toad Venom Compound Synthesized for Clinical Use: 5-MeO-DMT Succinate

‘Pharmacopeia’ Season Finale Features Cutting Edge Psychedelic Research

The Role of Oxytocin in MDMA’s Prosocial Effects

The Ancestral Healing Power of Ayahuasca

Pharmacological Testing in Psychedelic Research

Catching Up with the Psychedelic Entourage Effect: Part 4 – CaaMTech

1...293294295 296 Page 294 of 296

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

July 2025 Psychedelic Patent Update

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and...

Psychedelics Show Promise for Treating Dementia

Catching Up with the Psychedelic Entourage Effect: Part 3 – Field...

Insight into Ayahuasca’s Antidepressant Effects

New Toad Venom Compound Synthesized for Clinical Use: 5-MeO-DMT Succinate

‘Pharmacopeia’ Season Finale Features Cutting Edge Psychedelic Research

The Role of Oxytocin in MDMA’s Prosocial Effects

The Ancestral Healing Power of Ayahuasca

Pharmacological Testing in Psychedelic Research

Catching Up with the Psychedelic Entourage Effect: Part 4 – CaaMTech

EDITOR PICKS

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY